168 related articles for article (PubMed ID: 34721029)
21. What Factors Hindered the Access to Essential Anticancer Medicine in Public Hospitals for the Local Population in Hubei Province, China.
Chen C; Feng Z; Ding Y; Yan Z; Wang J; Wang R; Feng D
Front Pharmacol; 2021; 12():734637. PubMed ID: 34630110
[No Abstract] [Full Text] [Related]
22. Does Pharmaceutical Pricing Transparency Matter? Examining Brazil's Public Procurement System.
Kohler JC; Mitsakakis N; Saadat F; Byng D; Martinez MG
Global Health; 2015 Aug; 11():34. PubMed ID: 26238110
[TBL] [Abstract][Full Text] [Related]
23. Towards equitable access to medicines for the rural poor: analyses of insurance claims reveal rural pharmacy initiative triggers price competition in Kyrgyzstan.
Waning B; Maddix J; Tripodis Y; Laing R; Leufkens HG; Gokhale M
Int J Equity Health; 2009 Dec; 8():43. PubMed ID: 20003422
[TBL] [Abstract][Full Text] [Related]
24. Comparative assessment of medicine procurement prices in the United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA).
Ewen M; Al Sakit M; Saadeh R; Laing R; Vialle-Valentin C; Seita A; Bunders J
J Pharm Policy Pract; 2014; 7(1):13. PubMed ID: 25379183
[TBL] [Abstract][Full Text] [Related]
25. Access to paediatric essential medicines: a survey of prices, availability, affordability and price components in Shaanxi Province, China.
Wang X; Fang Y; Yang S; Jiang M; Yan K; Wu L; Lv B; Shen Q
PLoS One; 2014; 9(3):e90365. PubMed ID: 24595099
[TBL] [Abstract][Full Text] [Related]
26. Global Outsourcing and Local Tendering Supply Chain Systems in the Public Healthcare Sector: A Cost Comparison Analysis, Namibia.
Nakambale HN; Bangalee V
Value Health Reg Issues; 2022 Jul; 30():1-8. PubMed ID: 34915421
[TBL] [Abstract][Full Text] [Related]
27. Time trends and regional variations in prices of anticancer medicines in China.
Zhang J; Hu S; Liu X; Liu X; Zhang J; Yang C; Fang Y
Front Pharmacol; 2024; 15():1397784. PubMed ID: 38813105
[TBL] [Abstract][Full Text] [Related]
28. The availability, price and affordability of essential antibacterials in Hubei province, China.
Wu G; Gong S; Cai H; Ding Y
BMC Health Serv Res; 2018 Dec; 18(1):1013. PubMed ID: 30594189
[TBL] [Abstract][Full Text] [Related]
29. Price Determinants of the Tendering Process for Pharmaceuticals in the Cyprus Market.
Petrou P; Talias MA
Value Health Reg Issues; 2015 Sep; 7():67-73. PubMed ID: 29698154
[TBL] [Abstract][Full Text] [Related]
30. Pharmaceutical pricing: an empirical study of market competition in Chinese hospitals.
Wu J; Xu J; Liu G; Wu J
Pharmacoeconomics; 2014 Mar; 32(3):293-303. PubMed ID: 24190661
[TBL] [Abstract][Full Text] [Related]
31. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
[TBL] [Abstract][Full Text] [Related]
32. High prices for generics in Australia - more competition might help.
Bulfone L
Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
[TBL] [Abstract][Full Text] [Related]
33. Medical service pricing and pharmaceutical supply chain coordination contracts under the zero-markup drug policy.
Zhou N; Li S; Zhao G; Li C; Yu N
Front Public Health; 2023; 11():1208994. PubMed ID: 37927883
[TBL] [Abstract][Full Text] [Related]
34. Reforming antiretroviral price negotiations and public procurement: the Mexican experience.
Adesina A; Wirtz VJ; Dratler S
Health Policy Plan; 2013 Jan; 28(1):1-10. PubMed ID: 22375026
[TBL] [Abstract][Full Text] [Related]
35. Impact of price deregulation policy on the affordability of essential medicines for women's health: a panel data analysis.
Liu J; Wang L; Liu C; Zhang X
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):625-631. PubMed ID: 28503962
[TBL] [Abstract][Full Text] [Related]
36. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
Roughead EE; Kim DS; Ong B; Kemp-Casey A
WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
[TBL] [Abstract][Full Text] [Related]
37. The 'Netflix plus model': can subscription financing improve access to medicines in low- and middle-income countries?
Cherla A; Howard N; Mossialos E
Health Econ Policy Law; 2021 Apr; 16(2):113-123. PubMed ID: 32122423
[TBL] [Abstract][Full Text] [Related]
38. Influence of Government Price Regulation on the Price, Volume and Spending of Antibiotics in China: A Controlled Interrupted Time Series Study.
Wushouer H; Luo Z; Guan X; Shi L
Int J Health Policy Manag; 2022 Feb; 11(2):218-223. PubMed ID: 32702801
[TBL] [Abstract][Full Text] [Related]
39. Evaluating access to oral anti-diabetic medicines: A cross-sectional survey of prices, availability and affordability in Shaanxi Province, Western China.
Yang C; Hu S; Zhu Y; Zhu W; Li Z; Fang Y
PLoS One; 2019; 14(10):e0223769. PubMed ID: 31618273
[TBL] [Abstract][Full Text] [Related]
40. Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis.
Wang N; Yang Y; Xu L; Mao Z; Cui D
BMC Public Health; 2021 Oct; 21(1):1883. PubMed ID: 34663282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
